Share on StockTwits

DexCom (NASDAQ:DXCM) CEO Terrance H. Gregg unloaded 13,607 shares of the company’s stock on the open market in a transaction dated Friday, August 22nd. The shares were sold at an average price of $44.46, for a total value of $604,967.22. Following the sale, the chief executive officer now directly owns 395,626 shares of the company’s stock, valued at approximately $17,589,532. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

DXCM has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, August 8th. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company. DexCom presently has a consensus rating of “Hold” and an average target price of $41.00.

DexCom (NASDAQ:DXCM) traded down 0.39% on Monday, hitting $43.91. 364,197 shares of the company’s stock traded hands. DexCom has a 52-week low of $25.49 and a 52-week high of $49.83. The stock’s 50-day moving average is $39.89 and its 200-day moving average is $38.97. The company’s market cap is $3.314 billion.

DexCom (NASDAQ:DXCM) last released its earnings data on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter in the previous year, the company posted ($0.14) earnings per share. The company’s revenue for the quarter was up 64.2% on a year-over-year basis. Analysts expect that DexCom will post $-0.32 EPS for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Receive News & Ratings for DexCom Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.